Bristol-Myers Squibb ESMO 2016 Investor Meeting

Bristol-Myers Squibb presented clinical trial data across multiple oncology indications at ESMO 2016, including Opdivo (nivolumab) results in head and neck cancer, bladder cancer, and non-small cell lung cancer. The presentation showcased patient-reported outcomes and durable responses across various CheckMate trials, along with emerging combination therapy candidates.